RA Capital Management — Science Meets Wall Street

RA Capital Management is a crossover life sciences investment firm that bridges the gap between private venture investing and public markets. Founded by Peter Kolchinsky, a virologist-turned-investor, the firm manages over $10 billion and is known for its rigorous, science-first approach to biotech investing.

Quick Answer

RA Capital Management is a crossover life sciences investment firm founded in 2001 by Peter Kolchinsky, PhD, a virologist-turned-investor, and based in Boston. It manages over $10 billion and bridges private (pre-IPO) and public biotech investing — funding companies in early rounds, anchoring their IPOs, and holding through public markets. Its science-first due diligence, run by a team heavy with PhDs and MDs, evaluates drug mechanisms, clinical trial design, and probability of approval, supported by its in-house TechAtlas disease-landscape mapping. Its appearance in a company's filings has historically read as a signal of scientific conviction. The 13F lags up to 45 days and excludes private holdings — a partial positioning signal, not investment advice.

---

Key Facts

Investment Philosophy

RA Capital's approach is defined by the crossover model:

• Private investments — funding biotech companies pre-IPO, often participating in Series A/B rounds
• Public markets — continuing to invest post-IPO, providing capital at multiple stages
• Science-first — every investment decision starts with the science. The team evaluates drug mechanisms, clinical trial design, and probability of success
• Engaged investing — often takes board seats and helps shape company strategy
• Flexible capital — can invest across the company lifecycle, unlike pure VCs or public-only funds

Key People

• Peter Kolchinsky, PhD — Founder and Managing Partner. Virologist by training (PhD from Harvard). Author of "The Great American Drug Deal." Thought leader on drug pricing and biotech innovation.
• Rajeev Shah — Managing Partner. Drives investment strategy alongside Kolchinsky.

Portfolio Approach

Why Track RA Capital?

RA Capital sees companies before the public market does. As a crossover investor, they invest privately and then continue to hold through IPOs — their presence in an IPO is often a strong signal of scientific conviction.

What you can learn:

• Crossover advantage — seeing companies early gives information edge
• Science matters — RA Capital's PhD-heavy team represents the gold standard of biotech analysis
• Drug pricing matters — Kolchinsky's work on drug economics provides macro insight

Track RA Capital's public positions with Freenance to see which biotech companies have the backing of one of the most scientifically rigorous firms in the business.

Try Freenance for free →

FAQ

What is a crossover fund?

A crossover fund invests in both private (pre-IPO) and public companies. RA Capital invests in biotech companies early in their lifecycle and often continues to hold shares after the company goes public, providing continuity of support.

Who is Peter Kolchinsky?

Peter Kolchinsky is the founder of RA Capital and a trained virologist (Harvard PhD). He's also a public intellectual — his book "The Great American Drug Deal" addresses drug pricing and innovation. He's one of the most respected voices in biotech.

How does RA Capital evaluate biotech investments?

RA Capital evaluates investments through rigorous scientific analysis — examining drug mechanisms, clinical trial design, therapeutic area dynamics, and probability of regulatory approval. The team includes numerous PhDs and MDs who review data at the molecular level.

How much does RA Capital Management have in AUM?

RA Capital has historically managed around $10 billion across its private and public life-sciences strategies. Because the firm invests across both pre-IPO and public companies, its total AUM is reported through regulatory filings such as Form ADV rather than fully captured in quarterly 13Fs. It is worth checking current disclosures for the latest reported figures.

What does RA Capital's 13F reveal about its biotech positions?

Based on public 13F filings, RA Capital's disclosed holdings show its public-market biotech and pharmaceutical positions, many of which it first backed while still private. Because the firm is a crossover investor, its appearance in a company's filings has historically been read as a signal of scientific conviction. The 13F lags by up to 45 days and excludes private holdings, so it reflects only part of the portfolio.

What is RA Capital's "Raven" approach to research?

RA Capital is known for its in-house mapping of disease and drug-development landscapes, sometimes referred to as its TechAtlas function, which it uses to chart competitive dynamics across therapeutic areas. This deep, science-first framework — built by a team heavy with PhDs and MDs — underpins how the firm evaluates pipelines and probability of approval. It reflects the firm's founding identity as scientists who became investors.

Related Articles

• Baker Bros Advisors — Profile of the Biotech Hedge Fund Titans
• OrbiMed Advisors — Profile of the Global Healthcare Investment Powerhouse
• Fidelity Management — Profile of an Active Management Powerhouse